Oryzon Genomics Initiates Phase I Trial for iadademstat in Myelodysplastic Syndrome
MADRID and CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the first patient has been dosed in an investigator-initiated Phase I dose-finding trial of iadademstat, Oryzon’s potent and selective LSD1 inhibitor, in combination with azacitidine in myelodysplastic syndrome (MDS), led by the Medical College of Wisconsin (MCW).
Oryzon Genomics has made a significant step forward in the treatment of myelodysplastic syndrome (MDS) with the initiation of a Phase I clinical trial for iadademstat in combination with azacitidine. The trial, led by the Medical College of Wisconsin (MCW), aims to determine the optimal dose of iadademstat for patients with MDS, a group of disorders characterized by inefficient production of blood cells.
Iadademstat is a potent and selective LSD1 inhibitor, a class of drugs that have shown promise in treating various types of cancer. By targeting the LSD1 enzyme, iadademstat is designed to regulate gene expression and potentially restore normal cell function in MDS patients.
Impact on Individuals:
For individuals with MDS, the initiation of this Phase I trial offers hope for a new treatment option that may improve outcomes and quality of life. If iadademstat proves to be effective in combination with azacitidine, it could potentially become a valuable addition to the treatment arsenal for MDS patients.
Impact on the World:
The development of new therapies for diseases like MDS is essential for advancing medical care and improving patient outcomes worldwide. Oryzon Genomics’ commitment to leveraging epigenetics to address unmet medical needs demonstrates the potential for innovative approaches to tackling complex diseases.
Conclusion:
Overall, the initiation of the Phase I trial for iadademstat in MDS marks a significant milestone in the field of oncology and represents a step forward in the search for effective treatments for this challenging disease. The results of this trial have the potential to impact both individual patients and the global healthcare landscape, offering new hope for those affected by MDS.
